EGFR and lung adenocarcinoma: Patients with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR)-activating mutations showed a significant progression-free survival (PFS) benefit with reduced side effects by treatment with tyrosine kinase inhibitor (TKIs) (5).